Trasylol in the management of abruptio placentae with consumption coagulopathy and uterine inertia.
A study was conducted on 40 patients with abruptio placentae complicated by intrauterine death of the fetus, consumption coagulopathy and uterine inertia. All patients had severe hyperfibrinolysis (FDP > 300 microgram/ml). Following correction of shock, amniotomy was performed, intrauterine pressure catheters were placed, and oxytocin infusions were begun in all cases. The diagnosis of uterine inertia was made when the cervix failed to dilate following six hours of this treatment. After diagnosing uterine inertia, 18 patients (group B) did not. All but one patient in group A showed a marked improvement in the associated consumption coagulopathy and a rapid reawakening of uterine activity with progress to spontaneous vaginal delivery. Thirteen patients in group B did not show prepartum improvement in consumption coagulopathy or a resumption of uterine activity. These patients required cesarean section. There were two maternal deaths in group B; the overall complication rate in this group was greater than in group A.
D000037:Abruptio Placentae / Q000150:complications / Q000188:drug therapy*; D007611:Aprotinin / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005313:Fetal Death / Q000150:complications*; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D007275:Injections, Intravenous; D010976:Platelet Count; D011247:Pregnancy; D014593:Uterine Inertia / Q000097:blood / Q000150:complications / Q000188:drug therapy*
D005340:Fibrinogen; D007611:Aprotinin